Neuren Pharmaceuticals 미래 성장

Future 기준 확인 0/6

Neuren Pharmaceuticals 의 수익과 수익은 각각 연간 2.6% 및 9.9% 감소할 것으로 예상됩니다. EPS는 연간 14.1% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 19% 로 예상됩니다.

주요 정보

-9.9%

수익 성장률

-14.1%

EPS 성장률

Pharmaceuticals 수익 성장	23.9%
매출 성장률	-2.6%
향후 자기자본 수익률	19.0%
애널리스트 커버리지	Good
마지막 업데이트	18 Nov 2024

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

OTCPK:NURP.F - 애널리스트의 미래 추정치 및 과거 재무 데이터 (AUD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	209	109	103	88	5
12/31/2025	114	58	115	87	6
12/31/2024	194	113	36	69	5
6/30/2024	193	117	119	120	N/A
3/31/2024	213	137	152	152	N/A
12/31/2023	232	157	185	185	N/A
9/30/2023	155	106	120	120	N/A
6/30/2023	78	55	54	54	N/A
3/31/2023	47	28	29	29	N/A
12/31/2022	15	0	4	4	N/A
9/30/2022	9	-3	-3	-3	N/A
6/30/2022	3	-7	-10	-10	N/A
3/31/2022	3	-7	-10	-10	N/A
12/31/2021	3	-8	-10	-10	N/A
9/30/2021	2	-10	-10	-10	N/A
6/30/2021	1	-12	-9	-9	N/A
3/31/2021	1	-11	-9	-9	N/A
12/31/2020	1	-9	-8	-8	N/A
9/30/2020	1	-8	-9	-9	N/A
6/30/2020	0	-8	-9	-9	N/A
3/31/2020	0	-9	-10	-10	N/A
12/31/2019	0	-11	-12	-12	N/A
9/30/2019	7	-6	-5	-5	N/A
6/30/2019	14	-1	2	2	N/A
3/31/2019	14	1	4	4	N/A
12/31/2018	14	3	6	6	N/A
9/30/2018	7	3	0	0	N/A
6/30/2018	1	3	-6	-6	N/A
3/31/2018	1	3	N/A	-6	N/A
12/31/2017	1	3	N/A	-6	N/A
9/30/2017	2	-2	N/A	-7	N/A
6/30/2017	3	-8	N/A	-8	N/A
3/31/2017	3	-10	N/A	-10	N/A
12/31/2016	3	-12	N/A	-12	N/A
9/30/2016	2	-14	N/A	-14	N/A
6/30/2016	0	-15	N/A	-17	N/A
3/31/2016	1	-14	N/A	-15	N/A
12/31/2015	2	-13	N/A	-13	N/A
9/30/2015	2	-11	N/A	-11	N/A
6/30/2015	3	-9	N/A	-8	N/A
3/31/2015	3	-9	N/A	-7	N/A
12/31/2014	3	-8	N/A	-6	N/A
9/30/2014	3	-10	N/A	-7	N/A
6/30/2014	3	-12	N/A	-7	N/A
3/31/2014	4	-11	N/A	-7	N/A
12/31/2013	5	-10	N/A	-7	N/A

애널리스트 미래 성장 예측

수입 대 저축률: NURP.F 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -9.9% ).

수익 vs 시장: NURP.F 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -9.9% ).

고성장 수익: NURP.F 의 수익은 향후 3년간 감소할 것으로 예상됩니다.

수익 대 시장: NURP.F 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -2.6% ).

고성장 수익: NURP.F 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -2.6% ).

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: NURP.F 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 19 %).

Neuren Pharmaceuticals 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Recent updates

Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome

Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration

Neuren Pharmaceuticals Limited Commences Phase 2 Trials of NNZ-2591 in PMS and PTHS

Neuren Pharmaceuticals Limited Commences Phase 2 Trial of NNZ-2591 in Angelman

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Neuren Pharmaceuticals Limited Receives FDA Approval for Angelman IND and Phase 2 Trial

Neuren Pharmaceuticals Submits Investigational New Drug Application to the US Food and Drug Administration for NNZ-2591

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20.000001 million in funding

Neuren Pharmaceuticals Limited Submits an Investigational New Drug (IND) Application to the US Food and Drug Administration (FDA) for NNZ-2591 to Treat Angelman Syndrome

Neuren Pharmaceuticals Limited Receives Clear and Constructive Guidance from the Fda Office of Neuroscience in preIND Meetings for Phase 2 Clinical Trials of Nnz2591

Neuren Successfully Completes Drug Substance Manufacturing for NNZ-2591 Phase 2 Trials

Neuren Pharmaceuticals Limited Adds Prader-Willi Syndrome to Pipeline with Compelling Results for NNZ-2591 in Pre-Clinical Model

European Commission Grants 3 NNZ-2591 Orphan Designations to Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited Receives Approval for Final Stage of NNZ-2591 Clinical Trial

Neuren Pharmaceuticals Limited Initiates Manufacture of Nnz-2591 for Phase 2 Trials

Neuren Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215561 million.

Neuren Pharmaceuticals Limited announced that it has received AUD 20.000012 million in funding

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20 million in funding

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견